TY - JOUR T1 - Seroprevalence of Antibodies to SARS-CoV-2 among Health Care Workers in Kenya JF - medRxiv DO - 10.1101/2021.03.12.21253493 SP - 2021.03.12.21253493 AU - Anthony O. Etyang AU - Ruth Lucinde AU - Henry Karanja AU - Catherine Kalu AU - Daisy Mugo AU - James Nyagwange AU - John Gitonga AU - James Tuju AU - Perpetual Wanjiku AU - Angela Karani AU - Shadrack Mutua AU - Hosea Maroko AU - Eddy Nzomo AU - Eric Maitha AU - Evanson Kamuri AU - Thuranira Kaugiria AU - Justus Weru AU - Lucy B. Ochola AU - Nelson Kilimo AU - Sande Charo AU - Namdala Emukule AU - Wycliffe Moracha AU - David Mukabi AU - Rosemary Okuku AU - Monicah Ogutu AU - Barrack Angujo AU - Mark Otiende AU - Christian Bottomley AU - Edward Otieno AU - Leonard Ndwiga AU - Amek Nyaguara AU - Shirine Voller AU - Charles Agoti AU - David James Nokes AU - Lynette Isabella Ochola-Oyier AU - Rashid Aman AU - Patrick Amoth AU - Mercy Mwangangi AU - Kadondi Kasera AU - Wangari Ng’ang’a AU - Ifedayo Adetifa AU - E. Wangeci Kagucia AU - Katherine Gallagher AU - Sophie Uyoga AU - Benjamin Tsofa AU - Edwine Barasa AU - Philip Bejon AU - J. Anthony G. Scott AU - Ambrose Agweyu AU - George Warimwe Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/13/2021.03.12.21253493.abstract N2 - Background Few studies have assessed the seroprevalence of antibodies against SARS-CoV-2 among Health Care Workers (HCWs) in Africa. We report findings from a survey among HCWs in three counties in Kenya.Methods We recruited 684 HCWs from Kilifi (rural), Busia (rural) and Nairobi (urban) counties. The serosurvey was conducted between 30th July 2020 and 4th December 2020. We tested for IgG antibodies to SARS-CoV-2 spike protein using ELISA. Assay sensitivity and specificity were 93% (95% CI 88-96%) and 99% (95% CI 98-99.5%), respectively. We adjusted prevalence estimates using Bayesian modeling to account for assay performance.Results Crude overall seroprevalence was 19.7% (135/684). After adjustment for assay performance seroprevalence was 20.8% (95% CI 17.5-24.4%). Seroprevalence varied significantly (p<0.001) by site: 43.8% (CI 35.8-52.2%) in Nairobi, 12.6% (CI 8.8-17.1%) in Busia and 11.5% (CI 7.2-17.6%) in Kilifi. In a multivariable model controlling for age, sex and site, professional cadre was not associated with differences in seroprevalence.Conclusion These initial data demonstrate a high seroprevalence of antibodies to SARS-CoV-2 among HCWs in Kenya. There was significant variation in seroprevalence by region, but not by cadre.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was funded by the Wellcome Trust (grants 220991/Z/20/Z and 203077/Z/16/Z), the Bill and Melinda Gates Foundation (INV-017547), and the Foreign Commonwealth and Development Office (FCDO) through the East Africa Research Fund (EARF/ITT/039) and is part of an integrated programme of SARS-CoV-2 serosurveillance in Kenya led by KEMRI Wellcome Trust Research ProgrammeAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kenya Medical Research Institute Scientific and Ethics Review Unit (KEMRI/SERU/CGMR-C/203/4085)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified data are avaialble upon reasonable request ER -